Filing Details
- Accession Number:
- 0001209191-10-001327
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2010-01-05 12:00:00
- Reporting Period:
- 2009-12-31
- Filing Date:
- 2010-01-05
- Accepted Time:
- 2010-01-05 17:38:32
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1339455 | Somaxon Pharmaceuticals Inc. | SOMX | Pharmaceutical Preparations (2834) | 200161599 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1346901 | Jeffrey Raser | Somaxon Pharmaceuticals, Inc. 3830 Valley Centre Drive, Suite 705-461 San Diego CA 92130 | Senior Vp, Sales And Marketing | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2009-12-31 | 5,000 | $1.07 | 92,174 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Footnotes
- This sale of shares of common stock underlying vested restricted stock units was effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted by the reporting person, with the proceeds remitted to the Company to cover the taxes withheld upon the vesting of 12,500 restricted stock units on December 31, 2009.
- Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $1.06 to $1.09 per share. The reporting person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
- Reflects the forfeiture on December 31, 2009 of 21,660 restricted stock units that expired unvested. The vesting of such restricted stock units depended upon the Company raising aggregate proceeds of $25 million from one or more financing or strategic transactions during 2009, and that condition was not met.
Billionaire Hedge Funds
